Fetal Genetic Risk of Isolated Cleft Lip Only versus Isolated Cleft Lip and Palate: A Subphenotype Analysis using Two Population-Based Studies of Orofacial Clefts in Scandinavia

Division of Epidemiology, Norwegian Institute of Public Health, Nydalen, Oslo, Norway.
Birth Defects Research Part A Clinical and Molecular Teratology (Impact Factor: 2.21). 02/2011; 91(2):85-92. DOI: 10.1002/bdra.20747
Source: PubMed

ABSTRACT BACKGROUND: Cleft lip only (CLO) and cleft lip and palate (CLP) are commonly regarded as variants of the same defect and are traditionally combined to form the single group of cleft lip with or without cleft palate (CL/P) prior to analysis. However, recent data have suggested that at least a subgroup of isolated CLO may be etiologically distinct from isolated CLP. METHODS: To explore fetal genetic risk of isolated CLO separately from isolated CLP, we performed a subphenotype analysis using two population-based studies of clefts in Scandinavia. One hundred twenty-one isolated CLO, 190 isolated CLP, and 592 control triads were available from Norway (1996–2001), and a further 76 isolated CLO and 107 isolated CLP triads were available from Denmark (1991–2001). Genotypes for 1315 SNPs in 334 autosomal cleft candidate genes were analyzed using two complementary statistical methods, Triad Multi-Marker (TRIMM; Shi et al., 2007)) and HAPLIN (Gjessing and Lie, 2006), to look for genetic associations across the two national samples. RESULTS: Both TRIMM and HAPLIN identified strong associations between FGF12 and isolated CLO in both populations. In addition, only TRIMM identified associations with IRF6 and VCL, and only HAPLIN found an association with CX43. When analyses were repeated on the larger sample of isolated CLP, no significant associations were found with FGF12, IRF6, VCL, or CX43. CONCLUSIONS: Despite some inconsistency in the pattern of associations across the two populations, the associations themselves were phenotype-specific. While both IRF6 and FGF12 have previously shown strong associations with isolated CL/P, the associations with VCL and CX43 are novel and warrant further investigation in other isolated CLO samples. Birth Defects Research (Part A), 2010. © 2010 Wiley-Liss, Inc.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cleft lip and/or cleft palate (CL/P) collectively are well known as being amongst the most common birth defects but we still have difficulty explaining why the majority of cases occur. In general, sporadic cases with no family history may be more related to environmental risks, while the presence of one or more affected relative in the same family strongly suggests that genetic factors are the main contributor. Orofacial clefts can occur in conjunction with other defects (syndromic CL/P) or as an isolated defect (non-syndromic - NSCL/P). CL/P syndromes have been studied intensively and appear to have a stronger genetic aetiology. Here we report on the relationship between syndromic and NSCL/P as a phenotypic spectrum resulting from coding or non-coding mutations respectively. We review certain abnormalities that are most frequently associated with CL/P, including dental, heart, brain, skin and certain types of cancer and examine some of the genes that are involved. We include the outcome of recent NSCL/P GWAS data and we will discuss how the genes at these loci might contribute towards clarifying the genetics of CL/P.
    European journal of medical genetics 04/2014; DOI:10.1016/j.ejmg.2014.04.003 · 1.49 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Prolongation of the cardiac QRS complex is linked to increased mortality and may result from drug-induced inhibition of cardiac sodium channels (hNav1.5). There has been no systematic evaluation in pre-clinical and marketed drugs of the additional potential mechanism of gap junction uncoupling. Using the human cardiac gap junction connexin 43 (hCx43), a dye transfer "parachute" assay to determine IC50 values for compound ranking was validated with compounds known to uncouple gap junctions. Uncoupling activity (and hNav1.5 inhibition by automated patch-clamp) was determined in a set of marketed drugs and a set of pre-clinical candidate drugs, each with information regarding propensity to cause QRS prolongation. Known gap junction uncouplers carbenoxolone, heptanol, meclofenamic acid, digoxin and a phorbol ester produced hCx43 IC50 values of 210, 2208, 264, 0.136 and 0.023μM, respectively. Amongst marketed drugs associated with QRS prolongation, 29% were found to uncouple hCx43 (IC50 < 50μM) while no uncoupling agents were found in drugs without QRS association. In pre-clinical candidate drugs, hCx43 and hNav1.5 IC50 values were typically within ∼3-fold, although no consistent margin over pre-clinical Cmax (free) was apparent for QRS prolongation. Instances were found of QRS prolonging compounds that uncoupled hCx43 with significantly less activity at hNav1.5. These results demonstrate that off-target uncoupling activity is apparent in drug and drug-like molecules. Although the full ramifications of Cx inhibition remain to be established, screening for hCx43 off-target activity could reduce the likelihood of developing candidate drugs with QRS prolongation risk.
    British Journal of Pharmacology 12/2013; 171(21). DOI:10.1111/bph.12554 · 4.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fast developing technologies in genomics have driven genetic studies of human diseases from classical candidate approaches toward hypothesis-free and genome-wide screening methods. Compared to the low-resolution cytogenetic techniques that were the only available methods to visualize genomic changes at the chromosomal level until some 15 years ago, genome-wide studies including analyses of copy number variation (CNV), genome-wide association and linkage studies, and exome sequencing (ES) provide more accurate information for unraveling the genetic causes of diseases. Moreover, genome sequencing (GS) which interrogates the genome of a single individual at the nucleotide resolution has also been applied in genetic studies. Here we review genomic approaches in craniofacial disorders, with the emphasis on orofacial clefts, and discuss the applications, advantages, limitations, challenges, and future perspectives. © 2013 Wiley Periodicals, Inc.
    American Journal of Medical Genetics Part C Seminars in Medical Genetics 11/2013; 163(4). DOI:10.1002/ajmg.c.31379 · 3.54 Impact Factor


1 Download
Available from